Vinyas Innovative Technologies Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0oi4dim0euu0d9pjpy6zl0xg.pdf

Key Takeaways


Order Book & Revenue Visibility

Sumukh Narendra: "Over the last two and a half decades, we have grown from a focused electronics manufacturing business into a trusted manufacturing partner serving some of the most demanding and highly regulated industries."

Capacity Expansion & Utilization

Sumukh Narendra: "On the aerospace and defense side, we have a long gestation period for qualification of the lines. So post the installation of the infrastructure, we need to qualify those, qualify the infrastructure with our customers as well. Keeping that in mind, we have started the process and we feel that by the time the qualification is completed, the capex will be in place to ensure that we are able to have smooth execution of the orders."

Strategic Initiatives: JV, US Subsidiary & New Verticals

Sumukh Narendra: "We recently joined a joint venture agreement with a leading Israeli defense company and we believe this partnership represents an important milestone in our evolution and reflects the confidence that global defense companies place in India's manufacturing ecosystem and in Vinyas' capabilities."

Margin Dynamics & Product Mix


Supply Chain & Risk


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin11% to 12% for FY27FY27 full year
Order inflow growth25% to 30% above FY26 (~INR960 crores)FY27, with large POs in H2
Revenue growth momentum30% to 35% sustained growthBeyond FY27
New capacity availableINR30 crores capex yielding 25,000 sq ftTwo to three months from call date (~Aug 2026)
Medical revenue contribution~5% of FY27 revenueFY27
Export revenue shareRoughly 50/50 domestic/exportGoing forward

Key Metrics

MetricFY26
Revenue₹518 cr
H2 Revenue~₹302 cr
EBITDA₹64.77 cr
EBITDA margin12.5%
Profit after tax₹30.87 cr
Order inflows~₹960 cr
Order book (as of 31 Mar 2026)₹1,309 cr, defense 85–90%
Order book execution timeline18–24 months
Capacity utilization (post expansion)35–40%
Peak revenue capacity (post expansion)₹2,000–2,100 cr
Exports share of revenue~50%
FY27 revenue growth outlook25–30% year-on-year
FY27 EBITDA margin guidance11–12%
FY27 order inflow growth expectation25–30% over FY26
FY27 medical revenue target~5% of total revenue